Atrial Fibrillation Detection
apoplex medical technologies specializes in the development of applications to support the detection of atrial fibrillation. There are approximately 1 million people with undiagnosed and untreated paroxysmal atrial fibrillation in Germany alone. SRA® is used to identify this high-risk group in a timely manner and
facilitate rapid initiation of therapy. Our stroke risk analysisSRA®+ bundles the detection of paroxysmal atrial fibrillation (pVHF) and thesubsequent cardiological assessment of relevant ECG sections into a holisticpreventive healthcare offer.
Targeted patient selection & follow-up
SRA®+ not only detects acute fibrillation, but can also detect an increased likelihood of paroxysmal atrial fibrillation during fibrillation-free episodes. Fast and precise results allow you to target the high-risk group while reducing the personnel and time required.
Including cardiological assessment
The telecardiological results are available within 24hours and can be used directly as parameters in making therapy-related decisions. This provides you with detection and diagnosis directly from one source. A qualified team of cardiologists makes the diagnosis.
Guaranteed
data security
Ensures the security of sensitive patient data by fulfilling the strictest requirements of MDCG 2019-16and BSI-CS 132.
Over 130 hospitals already rely on our services.
Clinical
evidence
Performance proven several times in numerous international studies.
The detection rate is doubled and false positives are 100% excluded. This relieves the burden on cardiology resources and reduces patient length of stay.
